Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients (Q33847261)

29 July 2017

title

Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients (English)

1 reference

29 July 2017

1 reference

4

Emiel J T Rutgers

1 reference

29 July 2017

Marieke E Straver

1

1 reference

29 July 2017

Tjeerd S Aukema

2

1 reference

29 July 2017

Renato A Valdes Olmos

3

1 reference

29 July 2017

Kenneth G A Gilhuijs

5

1 reference

29 July 2017

Margaret E Schot

6

1 reference

29 July 2017

Wouter V Vogel

7

1 reference

29 July 2017

Marie-Jeanne T F D Vrancken Peeters

8

1 reference

29 July 2017

publication date

4 February 2010

1 reference

29 July 2017

number of pages

8

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

inferred from page(s)

published in

1 reference

29 July 2017

volume

37

1 reference

29 July 2017

issue

6

1 reference

29 July 2017

page(s)

1069-1076

1 reference

Accuracy of clinical evaluation of locally advanced breast cancer in patients receiving neoadjuvant chemotherapy

29 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2869017

Is there a role for positron emission tomography in breast cancer staging?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2869017

Neoadjuvant chemotherapy for operable breast cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2869017

Primary systemic therapy of breast cancer.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2869017

Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2869017

Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2869017

Value of integrated PET/CT for lesion localisation in cancer patients: a comparative study.

5 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00259-009-1343-2

18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2869017

Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2869017

Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2869017

Monitoring primary breast cancer throughout chemotherapy using FDG-PET.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2869017

Fluorodeoxyglucose positron emission tomography with sentinel lymph node biopsy for evaluation of axillary involvement in breast cancer.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2869017

Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2869017

Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2869017

Predictive value of [18F]FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2869017

PET diagnostic accuracy: improvement with in-line PET-CT system: initial results

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2869017

Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2869017

Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis

29 October 2018

1 reference

12 December 2020

A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases

1 reference

12 December 2020

[18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy

1 reference

12 December 2020

Dynamic contrast-enhanced MRI for prediction of breast cancer response to neoadjuvant chemotherapy: initial results

1 reference

12 December 2020

Towards rational axillary treatment in relation to neoadjuvant therapy in breast cancer

1 reference

12 December 2020

Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation?

1 reference

12 December 2020

Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy

1 reference

12 December 2020

Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer

1 reference

12 December 2020

Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes

1 reference

12 December 2020

10.1007/S00259-009-1343-2

Identifiers

DOI

1 reference

29 July 2017

1 reference

29 July 2017

1 reference